REDWOOD CITY, Calif.,
March 9, 2016 /PRNewswire/ -- Genomic
Health, Inc. (Nasdaq: GHDX) today announced the update of the
German Association of Gynecological Oncology's (AGO's) treatment
guidelines to recognize Oncotype DX® as the only multi-gene breast
cancer test with the highest 1A level of evidence. The AGO
guidelines also reconfirmed Oncotype DX as the only multi-gene
expression test validated to provide predictive information on the
likelihood of chemotherapy benefit for women with early-stage,
hormone-receptor positive, HER2-negative invasive breast
cancer.
"The latest update by AGO supports public reimbursement in
Germany, one of our key European
markets, and furthers international growth as we continue to bring
precision medicine to breast cancer patients worldwide," said
Jim Vaughn, R.Ph. Chief Commercial
Officer, Genomic Health. "Together with a recently established
access program by the National Health Service in England and existing public reimbursement for
the Oncotype DX breast cancer test in Switzerland, Ireland, Greece and Spain, we continue to pioneer the delivery of
value-based testing to healthcare systems across Europe."
The updated AGO guidelines reflect newly published large
prospective Oncotype DX outcomes studies including TAILORx,
conducted by the ECOG-ACRIN Cancer Research Group under the
sponsorship of the U.S. National Cancer Institute (NCI), and
three-year data from the PlanB study, conducted by the West German
Study Group (WSG). Five-year results from PlanB will be presented
on Friday, March 11 at a plenary
session during the 10th European Breast Cancer
Conference (EBCC-10).
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer tests
applies advanced genomic science to reveal the unique biology of a
tumor in order to optimize cancer treatment decisions. The
company's flagship product, the Oncotype DX breast cancer test, has
been shown to predict the likelihood of chemotherapy benefit as
well as recurrence in invasive breast cancer. Additionally, the
test predicts the likelihood of recurrence in a pre-invasive form
of breast cancer called DCIS. With 600,000 patients tested in more
than 90 countries, the Oncotype DX tests have redefined
personalized medicine by making genomics a critical part of cancer
diagnosis and treatment. To learn more about Oncotype DX breast
cancer tests, visit: www.OncotypeDX.com or
www.mybreastcancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ:
GHDX) is the world's leading provider of genomic-based diagnostic
tests that address both the overtreatment and optimal treatment of
cancer, one of the greatest issues in healthcare today. With its
Oncotype IQ™ Genomic Intelligence Platform, the company is applying
its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout
the cancer patient journey, from diagnosis to treatment selection
and monitoring. The Oncotype IQ portfolio of genomic tests and
services currently consists of the company's flagship line of
Oncotype DX gene expression tests that have been used to guide
treatment decisions for more than 600,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid and tissue-based tests. The company is
based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on Twitter:
@GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of the test to
physicians, patients and payors. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the company's
ability to obtain or maintain public and private reimbursement in
key markets in the U.S. and abroad; the ability of test results to
change treatment decisions; the applicability of clinical study
results to actual outcomes; and the other risks set forth in the
company's filing with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the quarter ended September
30, 2015. These forward-looking statements speak only as of
the date hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks and service
marks are the property of their respective owners.
Logo
- http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/german-national-cancer-guidelines-distinguish-oncotype-dx-as-first-and-only-multi-gene-breast-cancer-test-with-1a-level-of-evidence-300232981.html
SOURCE Genomic Health, Inc.